Sanctuary Advisors LLC Makes New Investment in West Pharmaceutical Services, Inc. $WST

Key Points

• Sanctuary Advisors LLC purchased 4,155 shares of West Pharmaceutical Services worth approximately $1.49 million during the second quarter. Institutional investors and hedge funds collectively own 93.9% of WST.
• West Pharmaceutical Services exceeded quarterly expectations, reporting $2.37 in EPS on $872.3 million in revenue, with revenue up 13.8% year over year. The company guided for fiscal 2026 EPS of $8.85–$9.05.
• Analyst sentiment remains positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $368.08. WST also pays a quarterly dividend of $0.22 per share, yielding approximately 0.3%.

Sanctuary Advisors LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,155 shares of the medical instruments supplier's stock, valued at approximately $1,492,000.

Several other institutional investors and hedge funds have also made changes to their positions in WST. Addison Advisors LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth $28,000. Avalon Trust Co purchased a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $28,000. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $25,000. Bayban acquired a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $27,000. Finally, DV Equities LLC purchased a new position in shares of West Pharmaceutical Services in the fourth quarter worth about $28,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Up 0.6%

Shares of WST stock opened at $350.68 on Thursday. The stock has a 50 day moving average of $349.99 and a 200 day moving average of $302.68. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock has a market cap of $24.68 billion, a P/E ratio of 44.90, a P/E/G ratio of 2.44 and a beta of 1.15. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business's quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services's dividend payout ratio is 11.27%.

Analyst Upgrades and Downgrades

WST has been the topic of a number of recent research reports. KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an "overweight" rating in a research report on Thursday, July 2nd. Citigroup raised their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an "outperform" rating and a $447.00 price objective for the company. Barclays upgraded shares of West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Evercore reissued an "outperform" rating and set a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, West Pharmaceutical Services currently has an average rating of "Moderate Buy" and an average price target of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.